Advanced Biomed faces Nasdaq delisting after failing minimum bid price; appeals with reverse split plan

Advanced Biomed Inc.

Failed to regain minimum $1.00 bid price by Jan 14, 2026; Nasdaq notified delisting effective Jan 27, 2026.
Company appealed on Jan 21, 2026, staying suspension pending Nasdaq hearings panel decision.
Regain compliance plan includes reverse stock split approved Jan 12, 2026, effective on/after Feb 13, 2026.
No assurance that panel will grant continued listing or that compliance will be achieved.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.